Home/Xennials Therapeutics/Dr. Majid Tabesh
DM

Dr. Majid Tabesh

President and CEO

Xennials Therapeutics

Therapeutic Areas

Xennials Therapeutics Pipeline

DrugIndicationPhase
NTX-301Platinum-resistant/refractory advanced ovarian cancer, bladder cancer, and other solid tumorsPhase 1/2
NTX-301 + TemozolomideHigh-grade Glioma (IDH1 mutated or Wild-Type)Phase 1/2 (Planned Cohort)